Arbutus Biopharma (ABUS) Receives a Buy from Chardan Capital
In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Arbutus Biopharma (ABUS), with a price target of $5.00. The company’s shares closed last Friday at $3.03.
According to TipRanks.com, Nakae is a 4-star analyst with an average return of 8.3% and a 45.5% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Emergent Biosolutions, and NeuBase Therapeutics.
Arbutus Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $6.00.
See today’s analyst top recommended stocks >>
Based on Arbutus Biopharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.49 million and GAAP net loss of $13.86 million. In comparison, last year the company earned revenue of $653K and had a GAAP net loss of $23.32 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.